EN
Issuer Rating
Performance
Average
Risk
High
Recommendation
Sell
Market Cap
$ 1.78B
Shares in biotech Sarepta soar after FDA allows shipments of Elevidys to resume
After third patient death this year, HC Wainwright cuts TP on Sarepta to zero
Sarepta tanks after death of second teen taking its gene therapy; outlook 'cloudy'
